ARTICLE | Financial News
After Ally Bridge-backed series A, Shanghai's GenFleet looks to clinic
December 7, 2018 7:07 PM UTC
With eight preclinical candidates and an experienced management team, immunology company GenFleet Therapeutics Co. Ltd. (Shanghai, China) raised RMB120 million ($17.4 million) in an untranched series A round to bring its first therapy into clinic next year.
Ally Bridge Group led the round, which saw participation from Sinopharm Capital and CSPC, and existing investors HighLight Capital, Qian Long Yu Han and TF Capital...
BCIQ Target Profiles
Transforming growth factor (TGF) beta receptor 1 (TGFBR1) (ALK5)